Menu
Search
|

Menu

Close
X

Aptevo Therapeutics Inc APVO.OQ (NASDAQ Stock Exchange Global Select Market)

4.97 USD
-0.09 (-1.78%)
As of Jul 14
chart
Previous Close 5.06
Open 5.05
Volume 12,836
3m Avg Volume 32,586
Today’s High 5.14
Today’s Low 4.97
52 Week High 6.30
52 Week Low 1.18
Shares Outstanding (mil) 21.42
Market Capitalization (mil) 57.83
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY18
4
FY17
22
FY16
24
FY15
34
EPS (USD)
FY18
-0.631
FY17
-1.396
FY16
-5.697
FY15
-2.935
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
1.59
5.73
Price to Book (MRQ)
vs sector
1.12
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
36.45
16.72
LT Debt to Equity (MRQ)
vs sector
36.45
12.39
Return on Investment (TTM)
vs sector
-122.43
14.61
Return on Equity (TTM)
vs sector
-145.10
16.34

EXECUTIVE LEADERSHIP

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2401 4th Ave Ste 1050
SEATTLE   WA   98121-3460

Phone: +1206.8380500
Site:

Aptevo Therapeutics Inc. is a biotechnology company. The Company is focused on oncology and hematology therapeutics. The Company is engaged in the discovery, development, commercialization and sale of oncology and hematology therapeutics. The Company's technology is the ADAPTIR (modular protein technology) platform. The Company has approximately four products in the areas of hematology and infectious diseases, as well as various investigational-stage product candidates in immuno-oncology. The Company's investigational-stage product candidates include MOR209/ES414, ES210, ES425, Otlertuzumab and 5E3. Its technology can produce monospecific and multispecific immunotherapeutic proteins that bind to various targets. The Company's marketed products are WinRho SDF (Rho(D) Immune Globulin Intravenous (Human)), HepaGam B (Hepatitis B Immune Globulin Intravenous (Human)), VARIZIG (Varicella Zoster Immune Globulin (Human)), and IXINITY (coagulation factor IX (recombinant)).

SPONSORED STORIES